Soylife Effective for Bone Loss in Postmenopausal Women

Giessen, The Netherlands - A newly published study in the Journal of Clinical Endocrinology and Metabolism shows that SoyLife is effective in the prevention of bone loss in Chinese postmenopausal women(1). Researchers from the Chinese University of Hong Kong performed a double-blind, randomized, placebo-controlled study, for one year, on 203 Chinese postmenopausal women between the ages of 48-62 years. The women received either one of two isoflavone dosages (40 or 80 mg aglycones daily) or a placebo. In addition, all women were given 500 mg of calcium and 125 IU of vitamin D3.

Bone mineral density (BMD) and bone mineral concentration (BMC) of the whole body, lumbar spine and hip were measured at baseline and after one year of treatment. Analysis showed that women taking the high-dosed isoflavone treatment (80 mg) had a significant favorable change rate in BMC at total hip and the trochanter and intertrochanter, compared to the placebo. This effect was independent of calcium and vitamin D3. An increase of 1 mg of isoflavones per day was associated with a yearly increase of 0.018-0.028% of BMC at these bone sites. The researchers concluded that "isoflavones have a mild, but statistically significant effects on maintenance of BMC in the hip in postmenopausal women with low initial bone mass (1)."

“This is the 3rd study showing bone sparing effects with SoyLife. A minimum dose of at least 80 mg isoflavones per day seems to be efficaceous. The future will tell whether these effects can be related to the high daidzein content of SoyLife, as we will soon learn more about the interesting features about equol, an important metabolite of daidzein,” says Dr. Marian Verbruggen, R & D Director of Acatris. The main isoflavones components of SoyLife are daidzein (46.4%), glycitein (38.8%) and genistein (14.7%), when expressed in aglycones.

1. Chen et al. (2003) Soy Isoflavones Have a Favorable Effect on Bone Loss in Chinese Postmenopausal Women with Lower Bone Mass: A Double-Blind, Randomized, Controlled Trial. J Clin Endocrinol Metabolism 88:4740-4747.


Acatris, division of the Dutch Royal Schouten Group, is an international organization that produces, markets and distributes ingredients for the food, health and nutrition industry. The product portfolio contains branded ingredients such as SoyLife ® , FenuLife ® and LinumLife ™ .

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.